プレガバリンの世界市場

プレガバリンの世界市場は2030年までに19億米ドルに達する見込み

2024年に16億米ドルと推定されるプレガバリンの世界市場は、2030年には19億米ドルに達し、分析期間2024-2030年のCAGRは2.5%で成長すると予測されます。プレガバリン本レポートで分析したセグメントの1つである錠剤とカプセルは、CAGR 2.9％を記録し、分析期間終了までに13億米ドルに達すると予測されます。その他のタイプセグメントの成長率は、分析期間中CAGR 1.5％と推定されます。

米国市場は4億4,870万米ドルと推定、中国はCAGR 4.7％で成長予測

米国のプレガバリン市場は、2024年に4億4,870万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに3億6,360万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と2.1％と予測されています。欧州では、ドイツがCAGR 1.5%で成長すると予測されています。

世界の「プレガバリン」市場- 需要の急増とイノベーションの原動力は何か？

医療・規制状況はプレガバリン市場をどのように形成してきたか？

γ-アミノ酪酸（GABA）アナログであるプレガバリンは、神経因性疼痛、線維筋痛症、全般性不安障害（GAD）、てんかんの治療に不可欠な医薬品として台頭してきました。過去10年間、リリカ（ファイザー）のようなブランド製剤の特許切れに伴うジェネリック医薬品の承認は、市場にとって極めて重要な出来事であり、より広範なアクセシビリティと価格競争を促進しました。米国FDA、欧州医薬品庁（EMA）、日本の医薬品医療機器総合機構（PMDA）など主要地域の規制当局は、経口カプセル剤、経口液剤、徐放性錠剤など様々な剤形を順次承認しており、製品ポートフォリオの多様化が進んでいます。特に新興市場では、このような規制の明確化が進み、現地メーカーがより自由に参入できるようになっています。同時に、片頭痛や双極性障害など、プレガバリンの適応外使用が注目されているが、まだ議論の余地があります。また、北米におけるオピオイド危機に対する意識の高まりにより、処方パターンも変化しており、プレガバリンは慢性疼痛管理のための、より安全でオピオイドを使用しない代替薬とみなされるようになってきています。一方、ファーマコビジランスのデータや臨床診療ガイドラインの更新は、使用基準や投与パターンに影響を与え続けています。特にインドやブラジルのような国々では、知的財産のダイナミクスによってジェネリック医薬品間の競合が促進され、価格帯がさらに引き下げられ、採用が増加しています。誤用や依存のリスクをめぐる訴訟や規制当局の監視は依然として活発ですが、進化する医療政策と連動して市場の勢いは増し続けています。

進化する患者人口統計と疫学的動向が舞台を整える？

世界の人口動態と疫学の変化は、プレガバリン需要の最も重要な原動力の一つです。特に日本、ドイツ、イタリアなどの先進国では、高齢化が進んでおり、プレガバリンが処方される主な疾患である神経障害性疼痛や糖尿病性末梢神経障害の有病率が高くなっています。新興国ではヘルスケアへのアクセスが向上しているため、てんかんや線維筋痛症の未診断症例が治療の網にかかるケースが増えており、対象となる患者層が拡大しています。さらに、生活習慣病（特に糖尿病）の急増は、プレガバリンの主要な応用分野である糖尿病性神経障害の増加に直結しています。さらに、不安障害のような精神衛生上の問題に対する社会的認知の高まりは、特に都市化されデジタルに接続された集団において、薬理学的介入を求める人々の増加につながっています。デジタルヘルスツールや遠隔医療プラットフォームが普及したことで、このような疾患に対する意識の高まりが診断率を向上させ、プレガバリンの処方を間接的に後押ししています。また、COVID後の慢性疼痛や心理状態の急増も注目に値するが、これはCOVIDの長期にわたる症状と関連している可能性があり、需要をさらに増幅させています。農村部の人口が高齢化している国では、疼痛管理療法の拡大を目的とした国家保健プログラムが、ジェネリックプレガバリンメーカーに新たなミクロ市場を不注意にも作り出しています。

市場力学において地域的・技術的変化はどのような役割を果たすか？

ヘルスケアインフラ、製造能力、医療リテラシーの地域差は、複雑でありながら有望なプレガバリン市場地図を作り出しています。北米は先進的な医療制度と高い認知度により引き続き金額ベースで優位を保っているが、アジア太平洋はインド、中国、南米に牽引され、最も積極的な成長を見せています。これらの国々では、ジェネリック医薬品の現地生産、政府による価格規制、保険適用の拡大が重要な促進要因となっています。ラテンアメリカとアフリカの一部はまだ発展途上の市場ですが、国際的な援助プログラムや現地の医薬品の拡大により、医薬品の入手可能性が向上するため、潜在的な可能性を示しています。徐放性錠剤の開発など、ドラッグデリバリー・システムにおける主な技術発展は、治療コンプライアンスと患者の利便性を向上させており、医師の処方行動に影響を与える重要な要因となっています。製造プロセスの革新、特にエナンチオマー的に純粋な化合物の合成や、費用対効果の高い製造技術の拡張は、生産者の利幅の改善につながっています。さらに、ファーマコビジランスと医薬品安全性モニタリングにおけるAIの活用は、市販後調査を合理化し、規制の遅れを軽減しています。eコマースや患者直販の医薬品流通チャネルへの依存度の高まりも、特にデジタル成熟経済圏では、プレガバリンがエンドユーザーに届く方法を変えつつあります。このような地域的・技術的開発の融合が、より競争力のあるイノベーション主導のマーケットプレースを可能にしています。

プレガバリン市場の持続的成長の原動力は？

世界のプレガバリン市場の成長は、技術、最終用途動向、消費者行動の進化に根ざしたいくつかの要因によって牽引されています。まず、特許切れ後のジェネリック医薬品製造が広く採用されたことで、コストの障壁が大幅に下がり、所得階層を問わず医薬品が入手しやすくなりました。医薬品サプライチェーンが特にアジア太平洋地域で現地生産にシフトしたことで、流通のタイムラインも最適化され、輸入依存度も最小限に抑えられました。最終用途の面では、高齢化に伴い慢性疼痛（神経因性疼痛、帯状疱疹後神経痛、線維筋痛症）の有病率が高まっていることが、対処可能な市場を直接的に拡大しています。同時に、精神科医が全般性不安障害に対するプレガバリンの処方に慣れてきたことや、メンタルヘルスケアにおける併用療法の処方が増加していることも、需要に新たな局面をもたらしています。病院、ペインクリニック、メンタルヘルスセンターでは、標準的な治療プロトコルにプレガバリンを取り入れるケースが増えています。消費者行動の観点からは、ジェネリック医薬品への信頼の高まりと患者教育の改善により、長期にわたる薬理学的治療に対する受容性が高まっています。特に、プレガバリンの新しい放出メカニズムがしばしば提供するような、より少ない副作用とより高い有効性が約束された製剤の場合、患者は現在、長期使用薬物療法をより遵守しています。さらに、デジタルヘルスエコシステム（電話相談、電子処方箋、戸別配達）の台頭により、プレガバリンのような特殊な医薬品へのアクセスに対する惰性は減少しています。これらの要因が、製薬会社による的を絞ったマーケティング努力や保険償還の改善と相まって、市場は持続的拡大へと舵を切っています。

セグメント

タイプ（錠剤・カプセル、その他のタイプ）;流通チャネル（病院薬局、ドラッグストア・小売薬局、オンラインプロバイダー）;用途（てんかん、神経障害性疼痛、その他の用途）

調査対象企業の例（注目の42社）

• Amneal Pharmaceuticals
• Apotex Inc.
• Aurobindo Pharma Ltd.
• Cipla Limited
• Dr. Reddy's Laboratories
• Glenmark Pharmaceuticals Ltd.
• Hikma Pharmaceuticals PLC
• Intas Pharmaceuticals Ltd.
• Lupin Limited
• Medley Pharmaceuticals Ltd.
• Mylan N.V.（Viatris Inc.）
• Novartis AG
• Pfizer Inc.
• Rising Pharmaceuticals
• Sanofi
• ScieGen Pharmaceuticals Inc.
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries
• Torrent Pharmaceuticals Ltd.
• Zydus Lifesciences Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Pregabalin Market to Reach US$1.9 Billion by 2030

The global market for Pregabalin estimated at US$1.6 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2024-2030. Pregabalin Tablets & Capsules, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Other Types segment is estimated at 1.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$448.7 Million While China is Forecast to Grow at 4.7% CAGR

The Pregabalin market in the U.S. is estimated at US$448.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$363.6 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global "Pregabalin" Market - What's Fueling the Surge in Demand and Innovation?

How Has the Medical and Regulatory Landscape Shaped the Pregabalin Market?

Pregabalin, a gamma-aminobutyric acid (GABA) analog, has emerged as a vital pharmaceutical compound in the treatment of neuropathic pain, fibromyalgia, generalized anxiety disorder (GAD), and epilepsy. Over the past decade, the approval of generic versions following the patent expiry of branded formulations like Lyrica (by Pfizer) has been a pivotal moment for the market, catalyzing broader accessibility and price competitiveness. Regulatory bodies in major regions including the U.S. FDA, EMA, and Japan’s PMDA have progressively approved various formulations-oral capsules, oral solutions, and extended-release tablets-creating a more diversified product portfolio. This evolving regulatory clarity, especially in emerging markets, is enabling local manufacturers to enter the scene more freely. Simultaneously, off-label uses of Pregabalin, such as for migraine and bipolar disorder, are seeing increased attention, although still debated. Prescription patterns have also shifted due to heightened awareness of the opioid crisis in North America, with Pregabalin increasingly being seen as a safer, non-opioid alternative for chronic pain management. Meanwhile, pharmacovigilance data and updated clinical practice guidelines continue to influence usage norms and dosage patterns. Intellectual property dynamics, especially in countries like India and Brazil, have fostered competition among generics, further reducing price points and increasing adoption. While litigation and regulatory scrutiny over misuse and dependence risks remain active, the market momentum continues to build in tandem with evolving health policies.

Could Evolving Patient Demographics and Epidemiological Trends Be Setting the Stage?

Demographic and epidemiological transformations globally are among the most significant underlying drivers of Pregabalin demand. Aging populations, especially in developed nations like Japan, Germany, and Italy, are associated with a higher prevalence of neuropathic pain and diabetic peripheral neuropathy, key conditions for which Pregabalin is prescribed. As healthcare access improves in emerging economies, underdiagnosed cases of epilepsy and fibromyalgia are increasingly being brought into the treatment net, expanding the target patient pool. Furthermore, the sharp rise in lifestyle diseases-most notably diabetes-is directly correlating with an increase in diabetic neuropathies, a core application area for Pregabalin. Additionally, the growing societal recognition of mental health issues such as anxiety disorders is leading to more people seeking pharmacological interventions, especially in urbanized and digitally connected populations. This heightened disease awareness, bolstered by widespread digital health tools and telemedicine platforms, has improved diagnosis rates, indirectly boosting Pregabalin prescriptions. Also noteworthy is the post-COVID surge in chronic pain and psychological conditions, potentially linked to long COVID symptoms, further amplifying demand. In countries with aging rural populations, national health programs aimed at expanding pain management therapies have inadvertently created new micro-markets for generic Pregabalin producers.

What Role Do Regional and Technological Shifts Play in Market Dynamics?

Regional variations in healthcare infrastructure, manufacturing capacity, and medical literacy are creating a complex yet promising Pregabalin market map. North America continues to dominate in terms of value due to its advanced healthcare system and high awareness levels, while Asia-Pacific is showing the most aggressive growth, led by India, China, and South Korea. In these countries, local production of generics, government price caps, and expanding insurance coverage are critical enablers. Latin America and parts of Africa are still nascent markets but show latent potential as international aid programs and local pharmaceutical expansions improve drug availability. Technological advancements in drug delivery systems-such as the development of extended-release Pregabalin tablets-are improving treatment compliance and patient convenience, a key factor influencing physicians' prescribing behavior. Innovations in manufacturing processes, particularly in the synthesis of enantiomerically pure compounds and the scaling of cost-effective production techniques, are leading to improved margins for producers. Furthermore, the use of AI in pharmacovigilance and drug safety monitoring is streamlining post-marketing surveillance and reducing regulatory delays. The increasing reliance on e-commerce and direct-to-patient drug distribution channels is also changing how Pregabalin reaches end-users, especially in digitally mature economies. The convergence of these regional and technological developments is enabling a more competitive and innovation-driven marketplace.

What Is Powering the Sustained Growth of the Pregabalin Market?

The growth in the global Pregabalin market is driven by several factors that are firmly rooted in technology, end-use trends, and evolving consumer behavior. Firstly, the widespread adoption of generic manufacturing post-patent expiry has significantly lowered cost barriers, making the drug more accessible across income tiers. The pharmaceutical supply chain’s shift toward local production, especially in Asia-Pacific, has also optimized distribution timelines and minimized import dependency. On the end-use front, the escalating prevalence of chronic pain conditions-neuropathic pain, postherpetic neuralgia, and fibromyalgia-among aging demographics has directly expanded the addressable market. Simultaneously, psychiatrists’ increasing comfort with prescribing Pregabalin for generalized anxiety disorders and the uptick in prescriptions for combination therapy in mental health care have added a new dimension to demand. Hospitals, pain clinics, and mental health centers are increasingly incorporating Pregabalin in their standard treatment protocols. From a consumer behavior standpoint, there is greater receptivity to long-term pharmacological treatments due to increased trust in generics and improved patient education. Patients are now more compliant with extended-use medications, especially when formulations promise fewer side effects and higher efficacy, which Pregabalin’s newer release mechanisms often provide. Additionally, the rise of digital health ecosystems-teleconsultations, e-prescriptions, and doorstep delivery-has reduced the inertia in accessing specialized medications like Pregabalin. These factors, combined with targeted marketing efforts by pharmaceutical companies and better insurance reimbursement coverage, are collectively steering the market toward sustained expansion.

SCOPE OF STUDY:

The report analyzes the Pregabalin market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Tablets & Capsules, Other Types); Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers); Application (Epilepsy, Neuropathic Pain, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Amneal Pharmaceuticals
• Apotex Inc.
• Aurobindo Pharma Ltd.
• Cipla Limited
• Dr. Reddy's Laboratories
• Glenmark Pharmaceuticals Ltd.
• Hikma Pharmaceuticals PLC
• Intas Pharmaceuticals Ltd.
• Lupin Limited
• Medley Pharmaceuticals Ltd.
• Mylan N.V. (Viatris Inc.)
• Novartis AG
• Pfizer Inc.
• Rising Pharmaceuticals
• Sanofi
• ScieGen Pharmaceuticals Inc.
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries
• Torrent Pharmaceuticals Ltd.
• Zydus Lifesciences Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Pregabalin - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Prevalence of Neuropathic Pain Drives Demand for Pregabalin Therapies
  • Increasing Diagnosis of Generalized Anxiety Disorder Expands Addressable Market for Pregabalin
  • Growing Geriatric Population Propels Use of Pregabalin in Chronic Pain Management
  • Regulatory Approvals for Additional Indications Strengthen Business Case for Expanded Use
  • Generic Erosion Post-Patent Expiry Spurs Market Competition and Price Accessibility
  • Surge in Off-Label Prescriptions Throws Spotlight on Regulatory Oversight and Clinical Guidelines
  • Online Pharmacy Growth and Telemedicine Platforms Fuel Wider Distribution of Pregabalin
  • Concerns Over Dependency and Abuse Potential Drive Interest in Controlled Dispensing Protocols
  • Rise in Epilepsy Cases in Emerging Markets Generates Demand for Affordable Pregabalin Formulations
  • Combination Therapy Approaches in Psychiatry Accelerate Use of Pregabalin in Multimodal Treatments
  • Growing Demand for Non-Opioid Pain Management Strengthens Pregabalin Market Position
  • Technological Innovations in Drug Delivery Systems Boost Extended-Release Pregabalin Development
  • Increased Payer Focus on Cost-Effective Treatment Options Supports Generic Adoption
  • Post-Marketing Surveillance and Pharmacovigilance Shape Market Sentiment and Prescriber Behavior
  • Cross-Border Sales and Parallel Imports Create Opportunities and Compliance Challenges
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Pregabalin Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Pregabalin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Pregabalin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Pregabalin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Tablets & Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Tablets & Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Tablets & Capsules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Online Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Epilepsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Neuropathic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• JAPAN
  • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• CHINA
  • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• EUROPE
  • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Pregabalin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Pregabalin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Pregabalin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• FRANCE
  • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• GERMANY
  • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Pregabalin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Pregabalin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• INDIA
  • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 161: India Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Pregabalin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Pregabalin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Pregabalin by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Pregabalin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Pregabalin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Pregabalin by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030
• AFRICA
  • Pregabalin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Pregabalin by Type - Tablets & Capsules and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Pregabalin by Type - Tablets & Capsules and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Pregabalin by Type - Percentage Breakdown of Value Sales for Tablets & Capsules and Other Types for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Pregabalin by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Pregabalin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Pregabalin by Application - Epilepsy, Neuropathic Pain and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Pregabalin by Application - Percentage Breakdown of Value Sales for Epilepsy, Neuropathic Pain and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION